Lifestyle

Two Drug Companies Inflated Generic Drug Prices 1,000%. You May Be Owed a Refund.

By Mike Harper · May 11, 2026

For more than a decade — from 2009 through 2019 — two pharmaceutical companies allegedly coordinated with each other and with other generic drug manufacturers to fix prices, eliminate competition, and charge Americans more than ten times the market rate for medications they bought specifically because they couldn’t afford the brand-name versions.

A bipartisan coalition of 48 state attorneys general, including New York’s Letitia James, secured $17.85 million in settlements from Bausch Health and Lannett Company in February — the latest in an ongoing multistate antitrust litigation that has now produced more than $67 million in settlements from multiple generic drug companies. The claim window for consumers who were overcharged is still open. If you bought generic prescription drugs manufactured by Bausch or Lannett between May 2009 and December 2019, you may be eligible for a refund.

The scheme, as described by investigators, was brazen in both its scope and its cynicism. The companies manufactured medications to treat diabetes, cancer, ADHD, infections, heart disease, and other common conditions — drugs that millions of Americans take every month because they are the affordable option. Some companies in the broader scheme increased prices by 1,000 percent, coordinating with competitors through back-channel communications to ensure no single company undercut the others and triggered real price competition.

Connecticut Attorney General William Tong described the conduct plainly: “Lannett and Bausch both engaged in widespread conspiracies to jack up prices and block competition for generic prescription drugs. Their brazen collusion cost American families and our public healthcare programs millions of dollars.”

Lannett will pay $13.77 million and Bausch will pay $4.08 million under the two settlements. Both companies will also implement mandatory internal antitrust compliance reforms and cooperate with the ongoing multistate litigation against the remaining defendants — 30 corporate defendants and 25 individual executives who have not yet settled.

Who qualifies and how to file:

If you purchased generic prescription drugs manufactured by Lannett or Bausch in the United States between May 2009 and December 2019, you may be eligible for compensation. The settlement funds will be distributed to consumers across participating states after court approval and once the claims process formally opens.

To determine your eligibility or register interest in the claims process, visit AGGenericDrugs.com, call 1-866-290-0182 toll-free Monday through Friday during business hours, or email info@AGGenericDrugs.com. Affected states include New York, New Jersey, California, Texas, Florida, and 43 others.

The specific medications covered include a wide range of generic drugs. The settlement website lists the covered products by name and manufacturer. If you used a regular pharmacy during that decade and filled generic prescriptions, it is worth checking whether any of those medications are on the list.

These settlements are part of a larger ongoing case. Additional defendants — including Novartis and its subsidiaries, against whom a new complaint was filed the same day as the Bausch and Lannett settlements — are still in litigation. More settlement funds may be available in future distributions as the case continues toward trial in Connecticut.